Skip to main content
Top
Published in: Clinical Rheumatology 3/2005

01-06-2005 | Case Report

ENT Wegener’s granulomatosis can hide severe central nervous system involvement

Authors: B. Tumiati, G. Zuccoli, L. Pavone, C. Buzio

Published in: Clinical Rheumatology | Issue 3/2005

Login to get access

Abstract

The clinical manifestations of localised or early systemic forms of Wegener’s granulomatosis (WG) do not require immediate treatment to save the patient’s life and/or the function of a vital organ. The organs mainly involved are the ear, nose, throat (ENT) and lung, and the results of antineutrophil cytoplasmic antibody (ANCA) assays are frequently negative. We here describe three cases of the ANCA-negative early systemic form of WG with prevalent ENT involvement complicated by severe central nervous system (CNS) disease; in two cases, the only symptom was a mild headache. We conclude that, although apparently mild, the localised and early systemic forms of WG can hide CNS involvement and may require immediate treatment. This complication should be suspected and investigated in the case of patients with localised or early systemic disease especially in the presence of ENT involvement and negative ANCA assays.
Literature
1.
go back to reference Jayne D (2001) Update on the European Vasculitis Study Group trials. Curr Opin Rheumatol 13:48–55CrossRefPubMed Jayne D (2001) Update on the European Vasculitis Study Group trials. Curr Opin Rheumatol 13:48–55CrossRefPubMed
2.
go back to reference Lamprecht P, Gross WL (2004) A brief history of Wegener’s granulomatosis: on limited, localized, and generalized forms of the disease: comment on the article by WGET. Arthritis Rheum 50:334–335CrossRefPubMed Lamprecht P, Gross WL (2004) A brief history of Wegener’s granulomatosis: on limited, localized, and generalized forms of the disease: comment on the article by WGET. Arthritis Rheum 50:334–335CrossRefPubMed
3.
go back to reference Rao JK, Weinberger M, Oddone EZ, Allen NB, Landsman P, Feussner JR (1995) The role of antineutrophil cytoplasmic antibody (c-ANCA) testing in the diagnosis of Wegener granulomatosis. A literature review and meta-analysis. Ann Intern Med 123:925–32PubMed Rao JK, Weinberger M, Oddone EZ, Allen NB, Landsman P, Feussner JR (1995) The role of antineutrophil cytoplasmic antibody (c-ANCA) testing in the diagnosis of Wegener granulomatosis. A literature review and meta-analysis. Ann Intern Med 123:925–32PubMed
4.
go back to reference Drachman DA (1963) Neurological complication of Wegener’s granulomatosis. Arch Neurol 8:145–155 Drachman DA (1963) Neurological complication of Wegener’s granulomatosis. Arch Neurol 8:145–155
5.
go back to reference Nishino H, Rubino FA, DeRemee RA, Swanson JW, Parisi JE (1993) Neurological involvement in Wegener’s granulomatosis: an analysis of 324 consecutive patients at the Mayo clinic. Ann Neurol 33:4–9PubMed Nishino H, Rubino FA, DeRemee RA, Swanson JW, Parisi JE (1993) Neurological involvement in Wegener’s granulomatosis: an analysis of 324 consecutive patients at the Mayo clinic. Ann Neurol 33:4–9PubMed
6.
go back to reference Reinhold-Keller E, de Groot K, Holl-Ulrich K, Arlt AC, Heller M, Feller AC, Gross WL (2001) Severe CNS manifestation as the clinical hallmark in generalized Wegener’s granulomatosis consistently negative for antineutrophil antibodies. A report of 3 cases and a review of the literature. Clin Exp Rheumatol 19:541–549PubMed Reinhold-Keller E, de Groot K, Holl-Ulrich K, Arlt AC, Heller M, Feller AC, Gross WL (2001) Severe CNS manifestation as the clinical hallmark in generalized Wegener’s granulomatosis consistently negative for antineutrophil antibodies. A report of 3 cases and a review of the literature. Clin Exp Rheumatol 19:541–549PubMed
7.
go back to reference Leavitt RY, Fauci AS, Bloch DA et al (1990) The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum 33:1101–1107PubMed Leavitt RY, Fauci AS, Bloch DA et al (1990) The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum 33:1101–1107PubMed
8.
go back to reference Jennette JC, Falk RJ, Andrassy K et al (1994) Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 37:187–192PubMed Jennette JC, Falk RJ, Andrassy K et al (1994) Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 37:187–192PubMed
9.
go back to reference Murphy JM, Gomez-Anson B, Gillard JH, Antoun NM, Cross J, Elliott JD, Lockwood M (1999) Wegener granulomatosis: MR imaging findings in brain and meninges. Radiology 213:794–799PubMed Murphy JM, Gomez-Anson B, Gillard JH, Antoun NM, Cross J, Elliott JD, Lockwood M (1999) Wegener granulomatosis: MR imaging findings in brain and meninges. Radiology 213:794–799PubMed
10.
go back to reference Stone JH, Wegener’s Granulomatosis Etanercept Trial Research Group (2003) Limited versus severe Wegener’s granulomatosis: baseline data on patients in the Wegener’s granulomatosis eternacept trial. Arthritis Rheum 48:2299–2309CrossRefPubMed Stone JH, Wegener’s Granulomatosis Etanercept Trial Research Group (2003) Limited versus severe Wegener’s granulomatosis: baseline data on patients in the Wegener’s granulomatosis eternacept trial. Arthritis Rheum 48:2299–2309CrossRefPubMed
Metadata
Title
ENT Wegener’s granulomatosis can hide severe central nervous system involvement
Authors
B. Tumiati
G. Zuccoli
L. Pavone
C. Buzio
Publication date
01-06-2005
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 3/2005
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-004-1025-1

Other articles of this Issue 3/2005

Clinical Rheumatology 3/2005 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.